NCT04675489

Visual Outcomes After Vivity Toric IOL Implantation

Patient Satisfaction and Visual Outcomes After Bilateral Implantation of a Novel Non-Diffractive Extended Vision Toric Intraocular Lens

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: EVP Eye Care · Academic / Other
• Sex: All
• Age: 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate patient satisfaction after bilateral implantation of Vivity Toric Extended Vision Intraocular lens and visual outcomes.

Detailed description

To evaluate and report outcomes including postoperative uncorrected visual acuity, postoperative best corrected visual acuity, postoperative refractive error, and IOL rotational stability after Vivity Toric Extended Vision intraocular lens (IOL) implantation.

Conditions

• Refractive Assessment

Interventions

Type	Name	Description
OTHER	Procedure: Vivity Toric IOL	The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's Vivity Toric Extended Vision intraocular lens (IOL) for cataract patients. This innovative lens is an extended depth of focus IOL that has been reported to result in fewer visual disturbances than diffractive IOLs.

Timeline

• Start date: 2021-01-15
• Primary completion: 2021-12-13
• Completion: 2021-12-13
• First posted: 2020-12-19
• Last updated: 2022-01-18

Locations

1 site across 1 country: United States